메뉴 바로가기
주메뉴 바로가기
컨텐츠 바로가기

SITE MAP

Quratis

Tel : +82 2 866 0604   Fax : +82 2 867 0125   Email : info@quratis.com

CONTACT US

R&D

Core Technology

Adjuvant Platform Technology

Adjuvant Platform Technology?

  • Adjuvant is a substance used in combination with an antigen to enhance the in vivo cellular and humoral immune response to a particular antigen.
  • Alum, which was developed over 70 years ago, is the most widely used immune enhancer used in commercial vaccines.
  • In recent years, many researches have been achieved on innate immunity, and an innate immunity enhancer is being used as an adjuvant.
  • Thus, the adjuvant can be used as a vaccine for various diseases by replacing only specific antigens, and we are working on applying them to various fields.

History of Vaccines

1700~ 1850~ 1900~ 1950~ 1980~

  • 1798

    Smallpox
    vaccine

  • 1813

    Congress creates
    national Vaccine
    Agency

  • 1855

    MA passes first US law
    mandating vaccination
    for schoolkids

  • 1885

    Rabies
    vaccine

  • 1886

    Typhoid
    vaccine

  • 1891

    Glycerin used
    to reduce germs
    in vaccines

  • 1896

    Cholera
    vaccine

  • 1923

    Diphtheria
    vaccine

  • 1924

    Tetanus
    vaccine

  • 1926

    Discovery of
    aluminum
    salt as adjuvant

  • 1925/1927

    Pertussis &
    Tb vaccines

  • 1935

    Yellow fever
    vaccine

  • 1936

    Influenza
    vaccine

  • 1955

    Polio
    vaccine

  • 1963

    Measles
    vaccine

  • 1967

    Mumps
    vaccine

  • 1969

    Rubella
    vaccine

  • 1970

    Anthrax
    vaccine

  • 1974

    Meningitis
    vaccine

  • 1977

    Pneumonia
    vaccine

  • 1981/1986

    Hep B & Hep
    Avaccines

  • 1995

    Varicella
    zoster vaccine

  • 1996

    Rotavirus
    vaccine

  • 2006

    HPV & shingles
    vaccines

Developing Next-generation Adjuvant

CPP Platform

Numerous trials, cell/bacterial penetration peptide drug delivery platform technology

Applicable to all antibiotics, antiviral drugs, anticancer drugs-infinite scalability

High-efficiency bacterial/cell penetrating peptide sequence discovery

· Construction of Escherichia coli library system expressing random peptide-GFP protein for discovery of highly efficient Mycobacterium tuberculosis penetrating peptides
· Verification of high-efficiency penetrating peptide permeability for bacteria (Mycobacterium spp., E. coli) and cells (Human macrophage, etc.)

Construction of a random peptide-GFP expression library

GFP protein expression E. coli candidate identification and MPP sequence analysis

Discovery of penetrating peptides targeting Mycobacterium smegmatis (left) and human macrophages (THP-1 cell line, right)